Disease Spotlight: Prostate Cancer


Study Says Targeted Biopsy with MRI Reduces Overdiagnosis of Prostate Cancer by Half

December 12, 2022

In a study of nearly 18,000 men who had prostate cancer screening, researchers found the use of pre-biopsy magnetic resonance imaging (MRI) for those with elevated prostate-specific antigen (PSA) levels and reserving MRI-targeted biopsy for those with PI-RADS scores of 3 to 5 reduced the risk of detecting clinically insignificant cancers by half.

Could an Emerging AI Platform Supplant Traditional MRI for Assessing Prostate Cancer?

December 07, 2022

The Food and Drug Administration has granted 510(k) clearance to iQuest (Avenda Health), an artificial intelligence (AI) platform that combines findings from magnetic resonance imaging (MRI), pathology reports and biopsy results to facilitate three-dimensional mapping of prostate cancer.

Study Assesses PET Agent for Detecting Pelvic Lymph Node Metastases in Patients with Prostate Cancer

December 06, 2022

For patients recently diagnosed with prostate cancer, the emerging positron emission tomography (PET) agent 18F-rhPSMA-7.3 reportedly has a 96 percent specificity rate for detecting pelvic lymph node metastases, according to Phase 3 study results recently presented at the 22nd Annual Scientific Meeting of the Society of Urologic Oncology (SUO).

Can MRI-Based Prostate Cancer Screening be a Viable Alternative to PSA Testing?

December 01, 2022

In what may be the first study to assess the effectiveness of biparametric magnetic resonance imaging (MRI) for prostate cancer screening in a large cohort, researchers found that MRI screening had a significantly lower false positive rate and significantly higher positive predictive values (PPVs) than prostate-specific antigen (PSA)-based screening.